Telix Pharmaceuticals Ltd
ASX:TLX
Intrinsic Value
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. [ Read More ]
The intrinsic value of one
TLX
stock under the Base Case scenario is
9.15
AUD.
Compared to the current market price of 14.91 AUD,
Telix Pharmaceuticals Ltd
is
Overvalued by 39%.
Telix Pharmaceuticals Ltd's market capitalization is 4.8B AUD.
TLX stock price is 14.91 AUD.
TLX stock (9.15 AUD) is 39% less than its price (14.91 AUD).
TLX stock (14.66 AUD) is 2% less than its price (14.91 AUD). Open Relative Valuation
TLX's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 16%.
TLX's ROE (Return on Equity) for the past 12 months is very low and is equal to 5%.
TLX's short-term assets (225m AUD) exceed its short-term liabilties (157m AUD).
TLX's long-term assets (398m AUD) exceed its long-term liabilties (249m AUD).
TLX's Revenue is forecast to grow at a rate of 26% per year over the next 3 years.
TLX's Revenue has grown by an exceptional 214% over the past 12 months.
TLX's ROE (Return on Equity) has significantly increased in the last 3 years from -60% to 5%.
TLX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -53% to 16%.
TLX has positive Operating Income for the last twelve months.
TLX has positive Net Income for the last twelve months.
TLX has positive Gross Profit for the last twelve months.
TLX has positive Free Cash Flow for the last twelve months.
TLX's Revenue has been growing by an exceptional 359% per year for the last 3 years.
TLX's D/E (Debt to Equity) is very low and is equal to 0.11.
TLX has negative three-year average ROE (Return on Equity): -119%. The company is not efficient at transforming stockholders' equity into net income.
TLX has negative three-year average ROIC (Return on Invested Capital): -69%. The company is not efficient at using invested capital to generate operating income.
TLX has negative Net Debt. This means that the company has more cash and short-term investments (123m AUD) than debt (16m AUD).
TLX's Altman Z-Score is very high and is equal to 8.07.
TLX doesn't generate enough operating income (18m AUD) to safely cover interest payments on its debt (-785k AUD).
Valuation Backtest
Telix Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
TLX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Telix Pharmaceuticals Ltd
Balance Sheet Decomposition
Telix Pharmaceuticals Ltd
| Current Assets | 224.8m |
| Cash & Short-Term Investments | 123.2m |
| Receivables | 64.8m |
| Other Current Assets | 36.8m |
| Non-Current Assets | 173.5m |
| Long-Term Investments | 12.3m |
| PP&E | 30.5m |
| Intangibles | 109.7m |
| Other Non-Current Assets | 21m |
| Current Liabilities | 157.4m |
| Accounts Payable | 32.8m |
| Accrued Liabilities | 55m |
| Other Current Liabilities | 69.6m |
| Non-Current Liabilities | 92m |
| Long-Term Debt | 15.9m |
| Other Non-Current Liabilities | 76.1m |
Earnings Waterfall
Telix Pharmaceuticals Ltd
|
Revenue
|
502.5m
AUD
|
|
Cost of Revenue
|
-188.2m
AUD
|
|
Gross Profit
|
314.4m
AUD
|
|
Operating Expenses
|
-296.8m
AUD
|
|
Operating Income
|
17.6m
AUD
|
|
Other Expenses
|
-12.4m
AUD
|
|
Net Income
|
5.2m
AUD
|
Free Cash Flow Analysis
Telix Pharmaceuticals Ltd
TLX Profitability Score
Profitability Due Diligence
Telix Pharmaceuticals Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Telix Pharmaceuticals Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
TLX Solvency Score
Solvency Due Diligence
Telix Pharmaceuticals Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Telix Pharmaceuticals Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLX Price Targets Summary
Telix Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
TLX
is 15.18 AUD
with a low forecast of 12.73 AUD and a high forecast of 19.43 AUD.
Shareholder Return
TLX Price
Telix Pharmaceuticals Ltd
| Average Annual Return | 80.2% |
| Standard Deviation of Annual Returns | 74.46% |
| Max Drawdown | -58% |
| Market Capitalization | 4.8B AUD |
| Shares Outstanding | 330 450 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Telix Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 158 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The firm's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one
TLX
stock under the Base Case scenario is
9.15
AUD.
Compared to the current market price of 14.91 AUD,
Telix Pharmaceuticals Ltd
is
Overvalued by 39%.
You don't have any saved screeners yet
